Program
isoquercitrin
Also written as “Kinisoquin™” and “Isoquercetin”.
Its studies are mostly in Venous Thromboembolism · COVID-19, led by 2 companies.
Drug pageIsoquercitrin: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AB Scienceits history only | 10 open or running | phase 2since Nov 9, 2020 | Nov 9, 2020 | none ahead |
| Quercis Pharmaits history only | 11 open or running | phase 3since Feb 28, 2025 | Feb 28, 2025 | Oct 31, 2027phase 3 · NCT06861088 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2020First study: phase 2 study in COVID-19New to AB ScienceAB Science · NCT04622865 · 200 enrolled · France
- Feb 28, 2025Quercis Pharma’s first study: phase 3 study in Venous ThromboembolismNew to Quercis PharmaQuercis Pharma · NCT06861088 · 480 planned · United States
Ahead
- Oct 31, 2027Primary completion: phase 3 study in Venous ThromboembolismQuercis Pharma · NCT06861088
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06861088Venous Thromboembolism · United States | 3 | Recruiting | Quercis Pharma | Oct 31, 2027 | 480 |
| NCT04622865COVID-19 · France | 2 | UNKNOWN | AB Science | Dec 2023 | 200 |
How it is read
Names in the registry
- “Kinisoquin™”, 1 entry
- “Isoquercetin”, 1 entry
Conditions, from the studies’ own filings
- Venous Thromboembolism, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.